Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791895 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs
A Phase 4 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 102
- Enrollment target
NCT00791895 is a Phase 4 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 102 participants.
The verdict
NCT00791895, a Phase 4 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 102 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the effectiveness of biphasic insulin aspart 30 in type 2 diabetics not achieving blood sugar levels when treated with oral anti-diabetics drugs (OADs) with or without basal insulin therapy.
Interventions
- DRUG biphasic insulin aspart 30
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2003-06-26 |
| Est. Completion | 2004-11-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00791895
The ClinicalTrials.gov registry entry for NCT00791895 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which biphasic insulin aspart 30 is the first listed.
NCT00791895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00791895 about?
NCT00791895 is a clinical study titled "Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs". This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the effectiveness of biphasic insulin aspart 30 in type 2 diabetics not achieving blood sugar levels when treated with oral anti-diabetics drugs (OADs) with or without basal insulin therapy.
What is the current status of trial NCT00791895?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 102 participants. The study started on 2003-06-26. Estimated completion is 2004-11-29.
What interventions are being tested in trial NCT00791895?
The interventions under investigation include: biphasic insulin aspart 30 (DRUG).
Who is sponsoring clinical trial NCT00791895?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.